Opella Helskea

History

2022: Recall of Phosphalugel in Russia due to exceeding the permissible lead limit

In March 2022, the Federal Service for Supervision in the Field health care () Roszdravnadzor on the basis of announced the decision of the company (Opella Helskea France SAS part of the group), Sanofi which is the holder of the marketing authorization P N012655/01 from the 05.03.2009 for drugs with the trade name "Phosphalyugel," to withdraw from circulation some batches of the drug due to the detection in them of exceeding the permissible daily limit of lead content. We are talking about the drug "Phosphalugel, oral gel 16 g, sachet (20), cardboard packs." More. here

2020: Sanofi created Opella Helskea in Russia

As it became known in early October 2020, the Russian representative office of the French pharmaceutical company Sanofi created a new trading company in the Russian Federation - Opella Helskea LLC. This is evidenced by the data of the Unified State Register of Legal Entities.

Former general manager of Sanofi Eurasia Irina Romanova has been appointed General Director of Opella Helskea. The new company will be engaged in the wholesale of pharmaceutical products. Additional activities are related to agents specializing in the wholesale of pharmaceutical products, products used for medical purposes, perfume and cosmetic products, including soap, and cleaning products.

Sanofi has created an Opella Helskea wholesale company in Russia

As part of Sanofi's "Play to Win" strategy announced in December 2019, the business unit of over-the-counter drugs and health products should become a global entity in its own right. This decision is aimed at making the over-the-counter business grow faster than the market. Among the various initiatives implemented in this context, a separate legal entity called Opella Helskea LLC was registered, "Yuri Mochalin, Sanofi's director of external relations in the Eurasian region, told Vademecum.

The creation of Sanofi a new company in Russia became known about a month and a half after the pharmaceutical giant registered the drug "Frisium" in the Russian Federation (also known as klobazam), which is used to combat epilepsy in children. The certificate is issued for five years. Earlier, the drug, which in Russia belongs to psychotropic, was not registered in the country, which is why criminal cases were initiated against citizens who brought it to the Russian Federation for sick children. The turnover of clobazam in the Russian Federation is limited. Its registration expired in 1997, the manufacturer initially did not plan to renew it.^[1]

Notes